STAT+: An AI biotech CEO sets the record straight on AI drug development hype
Brittany Trang·
·1 min read
·
0 reactions
·
0 comments
·
16 views
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
Original article
STAT News · Brittany Trang
Anonymous · no account needed
Discussion
0 commentsMore from STAT News
STAT+: Legend Biotech emerged as a rare market winner
STAT News·16
STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
STAT News·23
STAT+: China competition, ‘destruction’ at FDA gives agency chance to restructure, Rick Pazdur says
STAT News·19
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
STAT News·22
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
STAT News·22
STAT+: Allogene CEO David Chang stepping down
STAT News·26